Discovery-driven translational research in breast cancer is moving steadily from the study of cell lines to the analysis of clinically relevant samples that, together with the ever increasing number of novel and powerful tech-nologies available within genomics, proteomics and functional genomics, promise to have a major impact on the way breast cancer will be diag-nosed, treated and monitored in the future.